VIM and ovarian carcinoma: Further studies have shown that in ovarian cancer cells, the increased expression of βII- and βIII tubulin isotypes induces resistance to laulimalide (39), as does the downregulation of vimentin expression in human ovarian carcinoma cells [529,530].